Gå til indhold
Annonce
Erhverv For abonnenter

Novo får tæsk på børsen efter kæmpeoverskud

Trods rekord­omsætning og stigende overskud sendte investorerne Novo Nordisk-aktien ned på fondsbørsen onsdag. Forventningerne til 2016 skuffer

ARKIVFOTO. Medicingiganten Novo Nordisk fortsætter med at øge sin indtjening. Salget steg med 22 procent i 2015. (se diverse Ritzau historier) The new long-acting insulin Tresiba drug is seen on a Novo Nordisk production line, in this 2012 handout picture provided by Novo Nordisk. U.S. regulators on February 10, 2013 dealt a major blow to Novo Nordisk's hopes for its new long-acting insulin Tresiba by demanding the Danish drugmaker conduct additional clinical tests to assess potential heart risks. Novo, the world's biggest insulin maker, said the U.S. Food and Drug Administration (FDA) had requested additional data from a dedicated cardiovascular outcomes trial before it would consider approving Tresiba and related product Ryzodeg. The drugmaker - which is banking on Tresiba to keep it in the lead in diabetes care - said on Sunday it would not be able to provide the data in 2013 or 2014. Analysts said the FDA's stance could delay Tresiba until 2015 or 2016. REUTERS/Novo Nordisk/Handout (DENMARK - Tags: BUSINESS HEALTH) ATTENTION EDITORS - THIS IMAGE WAS PROVIDED BY A THIRD PARTY.NO COMMERCIAL OR BOOK SALES.NO SALES.NO COMMERCIAL USE.NO ARCHIVES. FOR EDITORIAL USE ONLY. NOT FOR SALE FOR MARKETING OR ADVERTISING CAMPAIGNS. THIS PICTURE IS DISTRIBUTED EXACTLY AS RECEIVED BY REUTERS, AS A SERVICE TO CLIENTS
Annonce
Annonce
Annonce
Annonce
Annonce